Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHLKarin Hohloch, Michael Pfreundschuh, Marita Ziepert et al.|SpringerPlus|2014Cited by 10